Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation.
Tau S, Chamberlin MD, Yang H, Marotti JD, Roberts AM, Carmichael MM, Cressey L, Dragnev C, Demidenko E, Hampsch RA, Soucy SM, Kolling F, Samkoe KS, Alvarez JV, Kettenbach AN, Miller TW.
Tau S, et al. Among authors: miller tw.
bioRxiv [Preprint]. 2024 Sep 27:2024.09.26.615177. doi: 10.1101/2024.09.26.615177.
bioRxiv. 2024.
PMID: 39386444
Free PMC article.
Preprint.